Foghorn Therapeutics/FHTX

$5.32

0.38%
-
1D1W1MYTD1YMAX

About Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.

Ticker

FHTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adrian Gottschalk

Employees

116

Headquarters

Cambridge, United States

FHTX Metrics

BasicAdvanced
$225.6M
Market cap
-
P/E ratio
-$2.35
EPS
3.16
Beta
-
Dividend rate
$225.6M
3.15854
$9.97
$2.70
164.98K
4.11
-28.5%
-34.11%
6.605
77.63%
10.37%
329.86%

What the Analysts think about FHTX

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
158.46% upside
High $20.00
Low $6.00
$5.32
Current price
$13.75
Average price target

FHTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-422.8% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$5.7M
-67.24%
Net income
$-24.1M
68.53%
Profit margin
-422.8%
414.48%

FHTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.31%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.73
-$0.70
-$0.34
-$0.57
-
Expected
-$0.73
-$0.74
-$0.75
-$0.76
-$0.63
Surprise
0.69%
-4.76%
-54.65%
-25.31%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Foghorn Therapeutics stock?

Foghorn Therapeutics (FHTX) has a market cap of $225.6M as of April 22, 2024.

What is the P/E ratio for Foghorn Therapeutics stock?

The price to earnings (P/E) ratio for Foghorn Therapeutics (FHTX) stock is 0 as of April 22, 2024.

Does Foghorn Therapeutics stock pay dividends?

No, Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next Foghorn Therapeutics dividend payment date?

Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Foghorn Therapeutics?

Foghorn Therapeutics (FHTX) has a beta rating of 3.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Foghorn Therapeutics stock price target?

The target price for Foghorn Therapeutics (FHTX) stock is $13.75, which is 158.46% above the current price of $5.32. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Foghorn Therapeutics stock

Buy or sell Foghorn Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing